Novartis replaces two research execs following a data-manipulation scandal that the company told the FDA about a month after its new drug (priced at $2.1 million) got approved for sale by the agency.
The Kaspar brothers who led the scientific development of $2 million gene therapy Zolgensma, have been replaced amid a data manipulation scandal that got Novartis rapped by the FDA
Novartis has replaced two research executives at the unit that makes Zolgensma, the world’s most expensive drug, following a data-manipulation scandal